Fund manager
Farallon Capital Management
Farallon Capital Management · Event-driven
Quarter ending 30 Jun 2026 · Filed 14 Aug 2026 · 82 positions · $16.9B reported
Event-driven and multi-strategy manager based in San Francisco. Added from a public list of the largest hedge fund managers.
Top holdings
| Company | Weight | Value (13F) |
|---|---|---|
| Revolution Medicines Inc (RVMD) | 15.0% | $2.5B |
| Electronic Arts Inc | 9.6% | $1.6B |
| Bridgebio Pharma Inc (BBIO) | 4.7% | $800.1M |
| Protagonist Therapeutics Inc (PTGX) | 4.6% | $778.2M |
| Exelixis Inc (EXEL) | 4.3% | $732.8M |
| Liquidia Corporation (LQDA) | 3.9% | $666.9M |
| Amazon Com Inc (AMZN) | 3.7% | $627.5M |
| Lantheus Hldgs Inc (LNTH) | 3.7% | $619.4M |
| Natera Inc (NTRA) | 3.6% | $602.2M |
| Unitedhealth Group Inc (UNH) | 3.1% | $528.1M |
| Thermo Fisher Scientific Inc (TMO) | 3.1% | $526.0M |
| Roivant Sciences Ltd | 3.0% | $506.4M |
| Aon Plc | 2.7% | $458.6M |
| Boston Scientific Corp (BSX) | 2.7% | $449.0M |
| Broadcom Inc (AVGO) | 2.6% | $435.1M |
Source: Form 13F-HR filing on SEC EDGAR (accession 0000908834-26-000432), for the quarter ending 30 Jun 2026, filed 14 Aug 2026. A 13F lists long US-listed equity positions only, filed up to 45 days after quarter end, so it is a look back, not a live portfolio. Values are as reported in the filing.
Open the interactive profile: buys and sells, track record, mimic portfolio